galcanezumab
Emgality · ATC code N02CD02
- Key facts
- Active substance
- galcanezumab
- Drug class
- Antimigraine
- ATC code
- N02CD02
- Authorisation
- centrally authorised across the EU (EMA)
- Dosage forms
- Emgality 120 mg solution for injection in pre-filled pen · Emgality 120 mg solution for injection in pre-filled syringe
- Marketing authorisation holder
- Eli Lilly Nederland B.V.
- Information as of
- 2026-10-27
Key facts
Galcanezumab (Emgality) is a monoclonal antibody against CGRP. It is used for migraine prophylaxis in adults who have at least 4 migraine days per month.
What it is used for
- Prophylaxis of migraine in adults with at least 4 migraine days per month
Dosing
- 120 mg subcutaneously once monthly, with a 240 mg loading dose as the initial dose
- Inject a missed dose as soon as possible, then resume monthly dosing
- Assess benefit within 3 months after starting; review need to continue regularly thereafter
- No dose adjustment for elderly patients or in mild to moderate renal or hepatic impairment
- Self-injection into abdomen, thigh, back of upper arm or gluteal region after training
- Safety and efficacy in children and adolescents not established
Contraindications
- Hypersensitivity to the active substance or any of the excipients
Important warnings
- Serious hypersensitivity (anaphylaxis, angioedema, urticaria), including delayed onset up to 4 weeks after dosing; discontinue immediately
- Patients with certain major cardiovascular diseases were excluded from studies; no safety data
- Record name and batch number of the biological product
Side effects
- Injection site pain (10.1%/11.6% for 120 mg/240 mg) and injection site reactions (9.9%/14.5%)
- Vertigo, constipation, pruritus, urticaria
- Rare: anaphylaxis, angioedema
- Most reactions mild or moderate
Interactions
- No pharmacokinetic drug interactions expected
Pregnancy and breastfeeding
- Limited data; as a precaution, preferably avoid during pregnancy
- Breast-feeding: risk cannot be excluded in the first days after birth; afterwards consider only if clinically needed
Summary of the official product information, written with AI (Claude, Anthropic) on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.
Common questions – ask Medelix
For patients
Package leaflet, verbatim
Authorisation and brand names by country
Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.
EU – centrally authorised (all member states)
- EmgalityEli Lilly Nederland B.V. · EMEA/H/C/004648
Source: European Medicines Agency (EMA), product information
Turkey
- EmgalityLİLLY İLAÇ TİC. LTD. ŞTİ. · 4 register entries
Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16
Brand names in 3 more European countries
- Iceland
- Emgality
- Liechtenstein
- Emgality
- Norway
- Emgality
EMA – Article 57 product data (EU/EEA), 2026-10-28
Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.
Other substances in the same group
Another question about this substance?
Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.
Sources
- European Medicines Agency. Emgality – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/emgality-epar-product-information_en.pdf
- TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
- Wikidata (CC0): ATC N02CD.
Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error
Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.